| Code | CSB-RA004888MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to tafasitamab, targeting CD19, a transmembrane glycoprotein exclusively expressed on B cells throughout their development from pre-B cells to mature B lymphocytes. CD19 functions as a critical co-receptor in the B-cell receptor complex, regulating B-cell activation, proliferation, and differentiation through signal transduction pathways. This target plays a significant role in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia, and other non-Hodgkin lymphomas, making it a valuable marker for investigating B-cell disorders and immune-related pathologies.
Tafasitamab is a humanized IgG1 monoclonal antibody with Fc modifications that enhance antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against CD19-positive cells. This biosimilar antibody serves as a research tool for studying B-cell biology, tumor immunology, and mechanisms of antibody-mediated cell depletion in oncology research. It enables investigators to explore CD19-targeted therapeutic strategies and evaluate immune effector functions in preclinical models of B-cell malignancies.
There are currently no reviews for this product.